scispace - formally typeset
K

Kaitlin Fier

Researcher at National Jewish Health

Publications -  14
Citations -  110

Kaitlin Fier is an academic researcher from National Jewish Health. The author has contributed to research in topics: Hypersensitivity pneumonitis & Pirfenidone. The author has an hindex of 6, co-authored 12 publications receiving 92 citations. Previous affiliations of Kaitlin Fier include Colorado School of Public Health.

Papers
More filters
Journal ArticleDOI

Looking ahead and behind at supplemental oxygen: A qualitative study of patients with pulmonary fibrosis

TL;DR: Starting and using supplemental oxygen on an everyday basis confers benefits while also presenting a significant number of challenges, which after starting oxygen, participants found to be more pronounced than anticipated.
Journal ArticleDOI

Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis

TL;DR: A longitudinal, pre-/post- study in which patient-reported outcome and activity data will be collected at baseline, immediately before daytime supplemental oxygen is initiated, and then once and again 9–12 months later, to assess the trajectories of outcomes over time.
Journal ArticleDOI

Seeking and sharing: why the pulmonary fibrosis community engages the web 2.0 environment

TL;DR: Clinicians may find it beneficial to encourage PF patients’ involvement in internet forums that foster dynamic, bi-directional information sharing to better understand PF and its impacts and to support others facing similar challenges.
Journal ArticleDOI

Informal caregivers experience of supplemental oxygen in pulmonary fibrosis.

TL;DR: Although O2 was a tangible and constant reminder of disease progression, over time ICs were able to adapt and accept their new lives with O2 and having O2 prescribers anticipate and recognize these challenges provides an opportunity to give support and guidance to ICs of PF patients who require O2.
Journal ArticleDOI

“Getting stuck with LAM”: patients perspectives on living with Lymphangioleiomyomatosis

TL;DR: Patients perceive the physical symptoms from LAM to be intrusive and limiting, and Therapeutic interventions should take aim at improving these perceptions.